Cargando…
ACT-16 THE POTENTIAL OF HYPOFRACTIONATED RADIOTHERAPY AND BEVACIZUMAB FOR GLIOBLASTOMA TREATMENT
INTRODUCTION: First-line bevacizumab (BEV) is now available as a treatment option for glioblastoma (GBM) patients with severe clinical conditions in Japan. However, the survival benefits remain controversial. As we have emphasized the combined effect of BEV and radiation therapy, the strategies; 1)...
Autores principales: | Hata, Nobuhiro, Mizoguchi, Masahiro, Kuga, Daisuke, Hatae, Ryusuke, Sangatsuda, Yuhei, Akagi, Yojiro, Amemiya, Takeo, Fujioka, Yutaka, Takigawa, Kosuke, Yoshitake, Tadamasa, Yoshimoto, Koji, Iihara, Koji |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7213105/ http://dx.doi.org/10.1093/noajnl/vdz039.065 |
Ejemplares similares
-
Mesenchymal glioblastoma-induced mature de-novo vessel formation of vascular endothelial cells in a microfluidic device
por: Amemiya, Takeo, et al.
Publicado: (2021) -
Molecular diagnosis of diffuse glioma using a chip-based digital PCR system to analyze IDH, TERT, and H3 mutations in the cerebrospinal fluid
por: Fujioka, Yutaka, et al.
Publicado: (2021) -
Current trend in treatment of glioblastoma in Japan: a national survey using the diagnostic procedure combination database (J-ASPECT study-glioblastoma)
por: Funakoshi, Yusuke, et al.
Publicado: (2021) -
Add-on bevacizumab can prevent early clinical deterioration and prolong survival in newly diagnosed partially resected glioblastoma patients with a poor performance status
por: Hata, Nobuhiro, et al.
Publicado: (2017) -
Update on Chemotherapeutic Approaches and Management of Bevacizumab Usage for Glioblastoma
por: Funakoshi, Yusuke, et al.
Publicado: (2020)